Jason Westin, M.D., MS, FACP, MD Anderson Cancer Center, Houston, TX

Recorded on January 21, 2025

Jason Westin, M.D., MS, FACP

Professor, Department of Lymphoma & Myeloma

Lead, Lymphoma & Myeloma Service Line

Director, Lymphoma Clinical Research

Section Chief, Aggressive and Indolent Lymphoma

MD Anderson Cancer Center

Houston, TX

In this episode, Dr. Jason Westin from MD Anderson Cancer Center in Houston, Texas explores CAR T-cell therapy, covering both current and emerging indications. He highlights the educational needs of patients and caregivers, as well as the essential role of community and academic collaboration before and after treatment. Dr. Westin also discusses the use of minimal/measurable residual disease (MRD) in treatment planning, future directions of CAR-T, and ongoing clinical trials. Tune in to stay up-to-date on the latest advancements in CAR T-cell therapy!

Feedback

This episode is supported by Allogene Therapeutics, Bristol Myers Squibb, Johnson
& Johnson & Legend Biotech, and Kite, a Gilead Company.